The combination of anti-PD-1/CTLA-4 was shown to enhance T cell function, however without a sufficiently large number of activated dendritic cells to cross-present and activate the T cells, a sub-optimal anti-tumor effect was observed. The gene discussed is CTLA4; the disease is neoplasm.